In addition to different complement components, we detected complement regulatory proteins in the human retina. It is increasingly evident that because excess cytolytic activity of the complement system may lead to tissue injury and inflammation, intrinsic regulatory mechanisms promote safe disposal of cell debris and avoid collateral damage. Combined actions of cell surface and fluid phase complement inhibitors provide an intrinsic regulatory mechanism to protect self-cells from complement-mediated lysis.
54,55 In humans, a number of membrane-bound complement inhibitors include decay-accelerating factor (CD55), membrane cofactor protein (CD46), CD59, and complement receptor 1 (CD35).
24,25,56 Similar to other brain
51 and eye
24,57 tissues, RGCs and axons acquire complement inhibitor molecules as a way to remain protected against excessive complement attack after injury.
30 However, there is evidence suggesting that in contrast to astrocytes and microglia, which express high levels of complement inhibitors and are well protected from complement-mediated damage, brain neurons express low levels of complement inhibitors and are highly susceptible to complement attack.
58,59 Our LC-MS/MS analysis detected CD35 expression in the human retina, and tissue immunolabeling demonstrated its localization mainly to nonneuronal cells. CD59 was not detected by proteomic analysis; however, consistent with previous observations,
24,25 double-immunolabeling studies indicated its localization to neuronal and nonneuronal cells. Neither proteomic nor immunohistochemical analysis detected a prominent alteration in the expression of these complement regulators in human glaucoma.
In addition to these membrane-bound complement inhibitors, proteomic analysis of the human retina detected fluid-phase complement inhibitors, including a CFH-related protein, C4 binding protein, and clusterin. These regulatory molecules, which have previously been shown to be present in the retina and the optic nerve,
30,60 do not completely block complement activation but are sufficient to prevent massive cell lysis and inflammation.
26 Findings of Western blot analysis and immunohistochemistry supported proteomic findings that CFH is constitutively expressed in retinal cells, including RGCs. Because of its affinity for C3b, this regulator protein prevents the assembly of the C3/C5-convertase (C3bBb/C3bC3bBb) of the alternative pathway by multiple mechanisms.
61–64 In addition to serving as a predominant regulator in the alternative complement pathway, CFH may affect the complement activation initiated by the classical pathway because it inhibits the alternative pathway serving as an amplification loop.
65 By virtue of its cofactor activity for C3b degradation, CFH can also restrict the assembly of the C3/C5-convertase (C4bC2a/C3bC4bC2a) of the classical pathway.
66 CFH-related proteins (such as CFH-related 4 detected in our proteomic analysis) also function as inhibitors of the complement pathway by blocking C5 convertase activity and interfering with C5b surface deposition and MAC formation, thereby controlling complement activation in a sequential manner to CFH function.
67 An important observation of this study was a trend toward downregulation of CFH expression in the glaucomatous human retina. Although the expression of classical pathway components appears to represent a relatively nonspecific response to tissue injury in glaucoma, this alteration in complement regulation would leave RGCs more vulnerable to complement-mediated lysis because insufficient inhibition of the downstream portions of the complement cascade may lead to the formation of a cytolytic membrane attack complex, as also supported by immunohistochemical findings.
Endogenous ligands of C1q, including apoptotic cells, can also bind fluid-phase complement inhibitors to prevent excessive complement activation. Dying cells first downregulate membrane-bound complement inhibitors to signal for phagocytosis. During overwhelming apoptosis or insufficient phagocytosis, apoptotic cells remaining in tissues for a longer time, so-called late apoptotic cells, may acquire the ability to bind complement activators, such as C1q and MBL, thereby initiating the complement cascade for rapid removal of cell debris.
68 Concomitant to this, cells acquire fluid-phase complement inhibitors, such as CFH, that compensate for the downregulation of membrane-bound complement regulatory proteins and allow enhanced complement-mediated recognition for phagocytosis while preventing overt inflammation because of the release of C5a and assembly of the membrane attack complex.
69 Therefore, the CFH downregulation that we detected in the glaucomatous human retina does not seem to be an expected component of the cell death-related tissue cleaning process but appears to facilitate collateral complement attack and inflammatory insult. This is supported by the findings of a recent study in which exogenous administration of CFH in an experimental model of autoimmune encephalomyelitis has resulted in a significant decrease in clinical score and inflammation by protecting neurons from complement opsonization, axonal injury, and leukocyte infiltration.
70
Thus, complement activation is under the tight control of complement inhibitors, and, depending on the balance between activation and regulatory inhibition, the final outcome may either be well-balanced complement activation necessary for tissue cleaning and healing or uncontrolled complement attack leading to collateral cell lysis, inflammation, and risk of autoimmunity.
26 Dysregulation of complement activation has been associated with multiple autoimmune diseases, and the disease-associated mutations identified in several complement components and regulators include genomic variations of the CFH gene, as reported in patients with AMD.
71–74 The precise role of complement in the etiology of these diseases is unresolved, but it seems clear that excess complement attack and local inflammation can exacerbate neuronal loss and that complement inhibition often results in neuroprotection,
52 as evident in RGC injuries.
8,75 Our findings suggest that imbalances in complement regulation may also contribute to the progression of neurodegenerative injury in glaucoma.
Among the 20 donor eyes used in our proteomic analysis, four glaucomatous and four nonglaucomatous eyes (samples 7, 8, 9, 10;
Figs. 2,
7) had AMD. However, we think this should not have affected our protein samples obtained from the peripheral retina of the macular region. In addition, AMD is not expected to cause any alteration in the inner retinal neurons, and AMD-related alterations in CFH expression have been associated primarily with the retinal pigment epithelium, which was not present in our samples. Concerning the possibility of genomic variations of the CFH gene in these donors, our Western blot data did not reveal a detectable difference in CFH protein expression between the donors with or without macular degeneration. However, it would be interesting to determine whether patients with glaucoma exhibit similar genomic variations of the CFH gene, although our present data support oxidative stress-related epigenetic factors in the altered regulation of CFH expression in glaucoma. It is also important to clarify how such coexisting conditions determine individual differences in susceptibility to glaucomatous injury. Because of the retrospective nature of our data collection, we considered that the assessment of a relationship between the proteomic findings and clinical variables would not be precisely informative. It should be recognized that despite their unique importance, studies using human donor tissues may be challenging because of the retrospective nature of data collection, difficulties excluding other disease conditions or treatment effects, and the possibility of perimortem tissue alterations. However, we were careful to minimize such confounding factors, and the utilized tissues of glaucomatous and nonglaucomatous donors were matched for donor age, cause of death, postmortem period, and clinical detection of macular degeneration. We hope that in vivo studies using transgenic models will be able to quantitatively assess neuronal damage and its relationship to complement regulation in glaucoma.